KLBF Stock Overview
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia.
Kalbe Farma Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||Rp1,600.00|
|52 Week High||Rp1,735.00|
|52 Week Low||Rp1,240.00|
|1 Month Change||-4.76%|
|3 Month Change||0%|
|1 Year Change||24.03%|
|3 Year Change||7.38%|
|5 Year Change||-8.83%|
|Change since IPO||13,720.55%|
Recent News & Updates
|KLBF||ID Pharmaceuticals||ID Market|
Return vs Industry: KLBF exceeded the ID Pharmaceuticals industry which returned 4.9% over the past year.
Return vs Market: KLBF exceeded the ID Market which returned 13.8% over the past year.
|KLBF Average Weekly Movement||3.7%|
|Pharmaceuticals Industry Average Movement||3.9%|
|Market Average Movement||6.1%|
|10% most volatile stocks in ID Market||11.7%|
|10% least volatile stocks in ID Market||2.9%|
Stable Share Price: KLBF is less volatile than 75% of ID stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: KLBF's weekly volatility (4%) has been stable over the past year.
About the Company
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic. It offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and CPG that are distributed to hospitals, pharmacies, and drug stores.
Kalbe Farma Fundamentals Summary
|KLBF fundamental statistics|
Is KLBF overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|KLBF income statement (TTM)|
|Cost of Revenue||Rp16.25t|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||71.45|
|Net Profit Margin||11.97%|
How did KLBF perform over the long term?See historical performance and comparison
2.2%Current Dividend Yield
Is KLBF undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for KLBF?
Other financial metrics that can be useful for relative valuation.
|What is KLBF's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does KLBF's PE Ratio compare to its peers?
|KLBF PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
KAEF Kimia Farma (Persero)
SOHO Soho Global Health
TSPC Tempo Scan Pacific
DVLA Darya-Varia Laboratoria
KLBF Kalbe Farma
Price-To-Earnings vs Peers: KLBF is expensive based on its Price-To-Earnings Ratio (22.4x) compared to the peer average (16.4x).
Price to Earnings Ratio vs Industry
How does KLBF's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?
Price-To-Earnings vs Industry: KLBF is expensive based on its Price-To-Earnings Ratio (22.4x) compared to the ID Pharmaceuticals industry average (16.5x)
Price to Earnings Ratio vs Fair Ratio
What is KLBF's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||22.4x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate KLBF's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of KLBF when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: KLBF (IDR1600) is trading above our estimate of fair value (IDR1568.37)
Significantly Below Fair Value: KLBF is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
How is Kalbe Farma forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KLBF's forecast earnings growth (11.1% per year) is above the savings rate (7%).
Earnings vs Market: KLBF's earnings (11.1% per year) are forecast to grow faster than the ID market (10.5% per year).
High Growth Earnings: KLBF's earnings are forecast to grow, but not significantly.
Revenue vs Market: KLBF's revenue (10.8% per year) is forecast to grow faster than the ID market (10.3% per year).
High Growth Revenue: KLBF's revenue (10.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: KLBF's Return on Equity is forecast to be low in 3 years time (17.1%).
Discover growth companies
How has Kalbe Farma performed over the past 5 years?
Past Performance Score4/6
Past Performance Score 4/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: KLBF has high quality earnings.
Growing Profit Margin: KLBF's current net profit margins (12%) are higher than last year (11.9%).
Past Earnings Growth Analysis
Earnings Trend: KLBF's earnings have grown by 6.7% per year over the past 5 years.
Accelerating Growth: KLBF's earnings growth over the past year (16.9%) exceeds its 5-year average (6.7% per year).
Earnings vs Industry: KLBF earnings growth over the past year (16.9%) underperformed the Pharmaceuticals industry 16.9%.
Return on Equity
High ROE: KLBF's Return on Equity (16.4%) is considered low.
Discover strong past performing companies
How is Kalbe Farma's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: KLBF's short term assets (IDR15,296.9B) exceed its short term liabilities (IDR3,747.3B).
Long Term Liabilities: KLBF's short term assets (IDR15,296.9B) exceed its long term liabilities (IDR786.2B).
Debt to Equity History and Analysis
Debt Level: KLBF has more cash than its total debt.
Reducing Debt: KLBF's debt to equity ratio has increased from 2.6% to 2.7% over the past 5 years.
Debt Coverage: KLBF's debt is well covered by operating cash flow (419.1%).
Interest Coverage: KLBF earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies
What is Kalbe Farma current dividend yield, its reliability and sustainability?
Dividend Score 3/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: KLBF's dividend (2.19%) is higher than the bottom 25% of dividend payers in the ID market (1.13%).
High Dividend: KLBF's dividend (2.19%) is low compared to the top 25% of dividend payers in the ID market (4.55%).
Stability and Growth of Payments
Stable Dividend: KLBF's dividend payments have been volatile in the past 10 years.
Growing Dividend: KLBF's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (49.2%), KLBF's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (96.2%), KLBF's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
- Vidjongtius (58 yo)
Mr. Vidjongtius has been President Director of PT Kalbe Farma Tbk. since June 5, 2017. He served as Corporate Secretary of PT.Kalbe Farma Tbk. since March 28, 2008 until June 14, 2017. Mr. Vidjongtius ser...
Experienced Management: KLBF's management team is seasoned and experienced (8.8 years average tenure).
Experienced Board: KLBF's board of directors are considered experienced (5.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
PT Kalbe Farma Tbk.'s employee growth, exchange listings and data sources
- Name: PT Kalbe Farma Tbk.
- Ticker: KLBF
- Exchange: IDX
- Founded: 1966
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: Rp74.414t
- Shares outstanding: 46.51b
- Website: https://www.kalbe.co.id
Number of Employees
- PT Kalbe Farma Tbk.
- Gedung KALBE
- Jl. Let. Jend. Suprapto Kav. 4
- Jakarta Raya
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/11 00:00|
|End of Day Share Price||2022/08/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.